Esperion Therapeutics (ESPR) Operating Income (2012 - 2026)

Esperion Therapeutics has reported Operating Income for 15 years, with the latest figure at -$6.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 70.22% year-over-year to -$6.6 million; the trailing twelve-month figure through Mar 2026 stood at $75.8 million (up 289.65% YoY), and the FY2025 full-year result was $60.3 million, up 10.79% from the prior year.
• Operating Income for Q1 2026 stood at -$6.6 million, down from $85.2 million in the prior quarter.
• The five-year high for Operating Income was $85.2 million in Q4 2025, with the low at -$52.4 million in Q2 2022.
• Historically, Operating Income has averaged -$13.4 million across 5 years, with a median of -$22.1 million in 2025.
• The largest YoY upside for Operating Income was 2028.35% in 2025 against a maximum downside of 130.57% in 2025.
• Esperion Therapeutics' Operating Income stood at -$42.5 million in 2022, then rose by 0.34% to -$42.4 million in 2023, then jumped by 89.57% to -$4.4 million in 2024, then soared by 2028.35% to $85.2 million in 2025, then slumped by 107.72% to -$6.6 million in 2026.
• The last three Operating Income figures came in at -$6.6 million (Q1 2026), $85.2 million (Q4 2025), and -$10.0 million (Q3 2025), per Business Quant data.